Paclitaxel and docetaxel are the two presently clinically available representatives of the new class of taxane drugs. They share major parts of their structures and mechanisms of action, but differ in several other aspects. For instance, there is a difference in their tubulin polymer generation, and docetaxel appears twice as active in depolymerization inhibition. In vitro docetaxel also tends to be more potent in different cell lines and investigational models. While in vitro and in vivo studies suggest that prolonged exposure to paclitaxel is better than a brief exposure, no such tendency is seen for docetaxel, indicating it to be a schedule-independent drug. Clinical studies have not confirmed an advantage for prolonged exposure to paclitaxel; but do show differences in the toxicity profiles of the two drugs. These topics will be addressed in detail.
Introduction
Recent clinical research on new drug development has been extremely interesting, mainly because of the introduction of two classes of drugs, the taxanes and the camptothecins, that already have longstanding histories, rendering the designation 'new 5 somewhat exaggerated. This review will focus on the development of taxanes.
Antimicrotubule agents have for many years been important anticancer agents, contributing significantly to the potentially curative treatment of diseases such as the malignant lymphomas, leukaemias and germ cell tumors. The search for new antimicrotubule agents during the past few decades has been less rewarding than had been hoped. Paclitaxel, extracted as early as the late 1960s from the bark of the Pacific Yew Taxus brevifolia, is the first compound with a taxene ring shown to possess antitumor activity [1] . Because of the scarcity of the drug, the difficulties in its isolation, extraction and formulation, the development of this antitumor agent was initially relatively slow. Once these problems were solved and after the discovery of its unique mechanism of action, development accelerated. The second drug in this new class of compounds is docetaxel, extracted in 1986 from the needles of the European Yew Taxus baccata [2] . This drug was more readily available because of the regenerating capacity of the source, and somewhat better soluble, and thus its development was more rapid than that of paclitaxel. This review will summarize preclinical and clinical data on both taxenes. Randomized studies comparing these two drugs have not yet been performed, so a true clinical comparison is not yet possible.
Biochemistry and mechanism of action
Paclitaxel consists of an eight-member taxane ring with a four-member oxetane ring and a bulky ester side chain at C-13 that is necessary for antitumor activity [3] but which can be modified (Fig. 1) . The chemical formula of paclitaxel is C 47 H 51 O 14 and its molecular weight is 853.9. It is highly lipophilic and insoluble in water, but soluble in Cremophor EL, polyethylene glycols 300 and 400, chloroform, acetone, ethanol and methanol. For clinical use paclitaxel is formulated in 50% Cremophor EL and 50% dehydrated alcohol.
Docetaxel differs from paclitaxel in the 10-position on the baccatin ring and in the 3'-position of the lateral chain, and has a chemical formula of C 4 3H53NO 14 and a molecular weight of 807.9. It is insoluble in water, but soluble in 0.1 N hydrochloric acid, chloroform, dimethylformamide, 95%-96% v/v ethanol, 0.1 N sodium hydroxide and methanol. The formulation used in the most recent clinical studies consists of 100% polysorbate 80.
Microtubules are among the most strategic subcellular targets of anticancer agents. Like DNA, microtubules are ubiquitous to all eukaryotic cells. They are composed of tubuline dimers consisting of an a-and a |3-subunit protein that polymerize and, with numerous microtubule-associated proteins (MAPs), decorate the exterior wall of the hollow micro tubule structure [4] . There is a continuous dynamic equilibrium between tubulin dimers and microtubules, i.e., a continuous balance between polymerization and depolymerization.
In addition to being an essential component of the mitotic spindle, and required for the maintenance of cell shape, microtubules are involved in a wide variety of cellular activities such as cell motility and transport between organelles within the cell [5] [6] [7] [8] . Furthermore, they may also have a role in modulating the interactions of growth factors with cell-surface receptors and the proliferative transmembrane signals produced by these interactions [5] [6] [7] [8] [9] . Many of the unique pharmacologic interactions of drugs with microtubules are caused by a dynamic equilibrium between microtubules and tubulin dimers [6, 10] . Any disruption of the equilibrium within the microtubule system would be expected to disrupt cell division and normal cellular activities in which microtubules are involved. Taxanes bind preferentially and reversibly to the p 1 -subunit of tubulin in the microtubules rather than to tubulin dimers [11] [12] [13] . The binding site to tubulin differs from the one of vinca-alkaloids and podophyllotoxins. While vincas inhibit polymerization and increase microtubule disassembly [14] , the binding of taxanes enhances polymerization of the tubulin into stable microtubules and inhibits microtubule depolymerization, thereby inducing the formation of stable microtubule bundles [14] [15] [16] [17] . This disruption of the normal equilibrium ultimately leads to cell death.
As an inhibitor of microtubule depolymerization, docetaxel is approximately twice as potent as paclitaxel [16, 17] . In addition, docetaxel generates tubulin polymers that differ structurally from those generated by paclitaxel [18] and does not alter the number of protofilaments in the microtubules, while paclitaxel does [19] .
In vitro cytotoxkity
Both taxanes have been found to be extremely potent against a wide variety of mouse and human cancer cell lines. Several in vitro studies have compared the activity of both compounds [20] [21] [22] [23] . Studies of paclitaxel have suggested a higher potency in prolonged-exposure experiments [14] .
Riou et al. compared the cytotoxicity of docetaxel and paclitaxel in several murine (P388, SVras) and human tumor cell lines (Calcl8, HCT116, T24, N417, KB). Docetaxel was found to be 1.3-to 12-fold more potent than paclitaxel after 96 hours of exposure, a result that could be explained by the higher affinity of docetaxel for microtubules [20] . There was partial cross-resistance of docetaxel to the P-glycoproteinpositive P388/DOX cell line resistant to doxorubicin, while for paclitaxel this cross-resistance was complete.
Using the sulforhodamine B assay, Kelland and Abel [21] compared the cytotoxic properties of both compounds in nine ovarian carcinoma cell lines, three of which were rendered resistant to platin derivatives. Both taxanes were much more cytotoxic than cisplatin, etoposide and doxorubicin in these cell lines. In the cisplatin-sensitive cell lines docetaxel was 1.3-to 3.9-fold more potent than paclitaxel after continuous exposure and 1.2-to 10-fold more potent after a 2-hour exposure.
No cross-resistance with either paclitaxel or docetaxel was found in the cell lines with acquired resistance to platinum. In another model, using in vitro colony formation of freshly explanted human tumor cells in a capillary soft agar cloning system, docetaxel was studied at concentrations of 0.025-10 jig/ml in short-term (1 hour) or continuous (14 days) incubations [22] . There was a dose-dependent inhibition of colony formation in breast cancer, lung cancer, ovarian cancer, colorectal cancer and melanoma. In addition, a 1-hour exposure to paclitaxel at 10 ng/ml resulted in inhibition of colony formation, but in a head-to-head comparison, 29 specimens were found to be more sensitive to docetaxel, while only 13 were more sensitive to paclitaxel. Thus, these data suggested a lack of complete cross-resistance between the two drugs and a higher potency of docetaxel in the majority of specimens evaluated. The latter was confirmed in a similar study comparing docetaxel and paclitaxel at final concentrations of 0.04, 0.4 and 4.0 ^mol/l [23] . Again there was a concentration-dependent anti-tumor cell activity for both drugs with all of the types of tumor cells responding, even those resistant to conventional antineoplastic agents. Docetaxel was significantly more potent by 1-hour incubation than paclitaxel (p -0.0002), which was also the case for the long-term (21-28 days) continuous exposure.
In vivo activity
Paclitaxel and, even more, docetaxel have also been studied in many murine tumor models and human tumor xenografts.
Paclitaxel was found to be active against intraperitoneal B16 melanoma, MX-1 breast cancer, and, to a lesser extent, CX-1 colon carcinoma, LX-1 lung tumor and ip P388 and L1210 [14] . It was inactive against subcutaneous CD8FJ mammary and C38 colon cancers and intravenous Lewis Lung carcinoma. Studies on schedule dependency in the P388 leukemia model suggested that an increased life-span was maximal when mice were treated every 3 hours, which approximates a continuous administration schedule [14] , but these studies did not use the maximum tolerable dose and therefore definitive conclusions can not be drawn.
In s.c. B16 melanoma docetaxel was 2.7 times as potent as paclitaxel [24] , and like paclitaxel, it was active against MX-1 mammary cancer [25] . In contrast to paclitaxel, docetaxel was active against C38 colon carcinoma, and also highly active against CX-1 colon carcinoma and LX-1 lung carcinoma [25, 26] .
Docetaxel was active in murine PO3 pancreatic carcinoma and s.c. C51 colon carcinoma as well, and in the xenografted KM 20L2 colon carcinoma, SK-MEL-2 melanoma and OVCAR-3, HOC8, HOC18 and HOC22 ovarian carcinoma [25, 27] . The activity of docetaxel was less pronounced in s.c. Lewis Lung carcinoma, L1210 and P388 leukaemia and Glasgow osteogenic sarcoma [24] .
While conclusions as to the schedule dependency of paclitaxel would be preliminary, there is no doubt that the activity of docetaxel is schedule-independent [24] .
Animal toxicology
Toxicology studies with paclitaxel in rodents were performed with intraperitoneal drug administration because of the toxicity of the vehicle, and because of volume constraints, in dogs the drug was given intravenously [28] .
The single-dose LD 10 in Sprague-Dawley rats was 138 mg/m 2 , and the LD 50 was 206 mg/m 2 . For the daily-times-five administration schedule these doses were 36 and 51 mg/mVday, respectively, in rats, and 67 and 82 mg/m 2 /day in CD2F1 mice. The single-dose toxic dose low (TDL) in beagle dogs was 45 mg/m 2 . The major toxic effect in rats and dogs was reversible myelosuppression. In rodents oligospermia was noted. Gastrointestinal toxicity was most pronounced in the daily-times-five schedule in dogs and consisted of diarrhea, mucosal ulcerations and emesis. In dogs hypotension was also observed which was believed to be related to cremophor EL.
For docetaxel the single-dose LD 10 in mice was 345 mg/m 2 , and the LD 50 was 414 mg/m 2 . In dogs the TDL was 15 mg/m 2 [29] . The main toxic effects of docetaxel were reversible myelosuppression and epithelial necrosis in the digestive tract. In mice, cumulative and reversible neurotoxicity was observed. Dogs experienced hypotension which was thought to be related to the vehicle Polysorbate 80.
Although there are minor differences, animal toxicology in general appears similar for paclitaxel and docetaxel, with similar target organs and more pronounced toxicity with repeated-administration schedules.
The recommended starting doses for phase I studies were based on one-third of the TDL in dogs for both drugs: 15 mg/m 2 for paclitaxel and 5 mg/m 2 for docetaxel.
Animal pharmacology
Pharmacokinetic data on paclitaxel in animals are scarce because of the lack of a sensitive assay in the era when the drug was being investigated only in the laboratory. None of the bioassays that were developed were suitable for detailed studies. With an assay with a detection limit of 0.1 u.M/1, however, it has been shown that in animals, paclitaxel was almost totally bound to proteins and had distribution and elimination half-lives of 2.7 and 42 minutes, respectively, in rabbits [30] .
In contrast a sensitive and selective high-performance liquid chromatographic (HPLC) assay for docetaxel was available early in its development [31] , and was used for studies in animals [29, 32] . In tumor-bearing mice t'/ 2 a and tV 2 p were 7 min and 1.1 hour, respectively. The pharmacokinetics were linear. The plasma clearance was 2.2 1/h/kg and the apparent volume of distribution at steady state 2.2 1/kg. The AUC at doses of 13-62 mg/kg ranged from 4.5 to 29.6 [ig/ml/h.
Administration of radiolabelled docetaxel led to a rapid diffusion into all tissues except those of the CNS, with the highest levels seen in liver, bile, intestines and gastric contents. The plasma protein binding in mice was 76%-89%, and the elimination was almost complete at 96 hours after administration. In the dog and mouse the primary route of elimination of radiolabelled docetaxel was by hepatic extraction and biliary excretion, while urinary excretion was < 10% [33] .
Phase I clinical trials
Phase I trials on paclitaxel were begun in 1983, but a high incidence of severe hypersensitivity reactions led to the premature closure of many of them. The hypersensitivity reactions occurred more frequently when paclitaxel was infused over a short period. Therefore, the infusion durations were extended to 6 or 24 hours and empiric prophylactic anti-allergic medication consisting of corticosteroids, antihistamines and 5HT 2 antagonists were given. Only quite recently has suggestive evidence been obtained that extension of the infusion duration might not have been necessary with the introduction of the premedication, which is one of the reasons that the optimal infusion duration has yet to be determined. The completed phase I studies, with doselimiting toxicities, maximum tolerated doses and recommended doses for phase II studies are listed in Table 1 [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] .
The major dose-limiting side effect of paclitaxel was neutropenia. Thrombocytopenia was uncommon. Other frequently occurring side effects were dose-dependent mucositis and peripheral neuropathy, arthralgias/myalgias, hypersensitivity reactions, alopecia, nausea, vomiting and cardiac rhythm abnormalities. Follow-up studies in the United States have all been performed using 24-hour infusion schedules and in Europe shorter infusion times have also been studied.
Patients with leukemias appear to tolerate a much higher dose [42] , with mucositis being dose-limiting at the dose of 390 mg/m 2 . The recommended dose for phase II studies in leukemias is 315 mg/m 2 . Using a 120-hour infusion every 3 weeks the MTD was 36 mg/ m 2 /day (total dose/course 180 mg/m 2 ), and the recommended dose for phase U studies 30 mg/m 2 /day (total dose per course 150 mg/m 2 ) [43] . Again, the dose-limiting toxicity was neutropenia. With this schedule there were no neuro or cardiac toxic effects, which can partly, but certainly not fully, be explained by the dose given. Responses were reported in all phase I studies with paclitaxel.
As neutropenia is the major dose-limiting side effect, attempts have been made to increase dose intensity by adding granulocyte-colony stimulating factor (G-CSF). On a 3-weekly schedule the gain was limited, with the MTD of a 24-hour infusion being raised to 300 mg/m 2 [44] . However, with interval shortening, a worthwhile increase in dose intensity might be achievable and this question is the subject on ongoing studies. Phase I studies combining paclitaxel with other cytotoxic agents have already been performed and many are still in progress. In view of the marginal overlap in toxicities and the suggested additive effect observed in vitro, cisplatin was the first drug added to paclitaxel [45] . The MTD of this combination was 200 mg/m 2 of paclitaxel and 75 mg/m 2 of cisplatin, given every 3 weeks. The dose-limiting toxicity was again neutropenia with a sequence dependency and was more pronounced when paclitaxel was administered after cisplatin. On the basis of pharmacokinetic data it was suggested that this interaction was due to a decrease in paclitaxel clearance when cisplatin preceded paclitaxel, and it is therefore recommended that paclitaxel be administered before cisplatin. With the addition of G-CSF to this regimen a dose of 250 mg/m 2 paclitaxel with 75 mg/m 2 of cisplatin was found to be feasible for repeated administrations [46] . With the combination of these two drugs neuromuscular toxicity becomes an important side effect [45, 46] . Ah" further combination regimens including paclitaxel have routinely used G-CSF.
Combining paclitaxel with doxorubicin creates major difficulties. Sequential [47] and concurrent [48] administrations have been studied. With sequential administration the MTD was 60 mg/m 2 of doxorubicin preceded by 125 mg/m 2 of paclitaxel. The most efficacious dose has not yet been defined. Dose-limiting toxicities were severe mucositis and neutropenia with infection [47] . With a concurrent 72-hour administration the dose-limiting toxicity is diarrhea with abdominal pain. The MTD was 60 mg/m 2 of doxorubicin with 180 mg/m 2 of paclitaxel [48] , but also at lower dose levels the number of hospital admissions for side effects is impressive, and whether this schedule should be further explored is questionable.
The data on the combination of paclitaxel with cyclophosphamide are still limited [49] . As for cisplatin there appears to be sequence-specific toxicity. The MTD in this study had not yet been reached by the time of the first publication, while toxicities mainly included neutropenia with fever. An ongoing study at the NCI is adding cisplatin to the above combination, and administration of a high dose of all three drugs appears feasible (44] .
Finally, several phase I studies combining paclitaxel with carboplatin are ongoing. One study, using target AUC for dosing of carboplatin, has reached MTD [51] . The dose-limiting toxicity was myelosuppression with a suggestion of cumulation. The MTD was defined as 135 mg/m 2 of paclitaxel with AUC -7.5 for carboplatin. In the phase I studies on docetaxel various schedules of drug administration have been tested (Table 2 ) [52] [53] [54] [55] [56] [57] . The major dose-limiting toxic effect throughout these studies was an early-onset, short-lasting, dosedependent, schedule-independent and non-cumulative neutropenia. Other side effects were mild paresthesias, infrequent hypersensitivity reactions, general alopecia, nausea, vomiting, diarrhea and skin reactions (ery- thema, desquamation and nail changes) and incidental fluid retention. Mucositis was mainly seen with longer durations of infusion, and was the main cause of complicated neutropenia. Cardiac toxicity was not reported.
Responses were reported in different tumor types. Based on considerations such as dose intensity, toxicity profile and absence of preclinical data suggesting any schedule dependency, the recommended dose and schedule for phase II studies was 100 mg/m 2 given as a 1-hour infusion every 3 weeks, without prophylactic measures for hypersensitivity reactions and no prophylactic antiemetics.
Phase I studies combining docetaxel with other cytotoxic drugs are underway. It appears feasible to combine high doses of docetaxel and cisplatin [58] . In contrast to paclitaxel [45] , there seems to be no sequencerelated difference in side effects, and docetaxel did not change the pharmacokinetics of cisplatin [59] .
Clinical pharmacology
HPLC assays for both paclitaxel [60] and docetaxel [31] were used for pharmacokinetics in several phase I trials. The pharmacokinetic parameters of paclitaxel and docetaxel are summarized in Table 3 .
The disposition of paclitaxel in plasma has been characterized by a biphasic model with a rather wide variability between the distribution and elimination phases [34-37, 39, 42] . It has been suggested that the pharmacokinetics of paclitaxel may be non-linear [61] . In patients treated by 3-hour infusions, proportionally greater increases in maximum drug levels at the end of the infusion (C^) and AUC in relation to dose were observed. Since clearance decreased with increasing dose, a non-linear elimination process was indicated.
The investigators fitted the pharmacokinetic data to a 2-compartment open model with a saturable secondorder process from the central to the peripheral compartments and first-order processes for return from the peripheral compartment and central elimination. Thus, changes in schedule may result in different total drug exposures. Although the drug is extensively protein-bound, it is rapidly eliminated from the plasma. The urinary excretion is only 1.4%-6.6%, thus making a minor contribution to the systemic clearance which therefore should be related to metabolism, biliary excretion, or tissue binding [9] .
Unlike as is suggested for paclitaxel, docetaxel disposition is not schedule-dependent. Pharmacokinetics are linear up to doses of 115 mg/m 2 [52, 55, 56] . The disposition was triphasic [52] and interpatient variability appears limited whereas intrapatient variability is considerable [55] . As for paclitaxel, docetaxel is largely and rapidly protein-bound [62] and its urinary excretion is limited to 9%.
For clinical use paclitaxel is formulated a.o in 50% cremophor EL. This vehicle has been shown to block the P-glycoprotein drug efflux pump in vitro. Interestingly, a pharmacokinetic study in patients treated with a 3-hour infusion of paclitaxel at a dose of 135-175 mg/ m 2 has shown that the concentrations of cremophor EL found in plasma were sufficient to inhibit PGP in vitro, suggesting that this effect may contribute to the observed antitumor effect of paclitaxel [63] .
Phase II clinical trials
In view of the responses observed with paclitaxel in phase I studies in chemotherapy-refractory patients with ovarian cancer, the initial focus in phase II studies was on this tumor type, although phase II studies in a wide variety of tumors have now been performed. One of the difficulties in summarizing these studies is the fact that different doses were applied in addition to different infusion durations, although the majority of studies were performed with the 24-hour infusion. For docetaxel the phase II programme is less focused on a specific tumor type, and all studies to the present have used only one dose and one duration of infusion, facilitating the interpretation of the results.
It should be noted that many of the docetaxel data cited in the following are from abstracts. Data in the final papers to be published in the coming year might differ to some extent. Also, more mature data on paclitaxel from randomized trials will soon be provided. (Table 4) Many phase II trials with paclitaxel have been performed and reported [64] [65] [66] [67] [68] [69] [70] [71] . As stated, the doses used in these studies were rather diverse and the strata not similar, thus preventing formulation of a straight foreward conclusion.
Ovarian cancer
In the first reported study [64] using paclitaxel doses of 110-250 mg/m 2 , 12 of 40 patients (30%) responded, including 6 (24%) of 25 patients progressing during cisplatin treatment, and 6 (40%) of 15 patients progressing after cisplatin-free intervals of at least 6 months. Two other early studies [65, 66] yielded overall response rates of 20% and 29%. Because overall response throughout the studies is the easiest to compare, and detailed information on responses in the different strata is frequently not yet published, all further data and those in Table 4 are given as overall response data. As the table indicates, there appears to be some extent of a dose-response relationship, with response rates varying between 19% with a dose of 135 mg/m 2 , to 36% with a dose of 250 mg/m 2 . Nevertheless, the data are still limited by patient numbers and we await randomized study results before drawing definitive conclusions.
The mean response duration at all dose levels is approximately 7 months. However, a large multinational multicenter trial with a bifactorial design, comparing 135 mg/m 2 and 175 mg/m 2 , and 3-hour and 24-hour infusions in a total of 312 patients [69] showed no significant difference in the response rates of the two doses or infusion schedules in the first 286 patients evaluable for response. Even more important, this study showed that toxic effects in 298 evaluable patients were more pronounced with the longer infusion duration, irrespective of dose, which suggests that the shorter infusion may be the most appropriate. Unfortunately, as already indicated, the majority of studies have been performed with the 24-hour infusion schedule. Docetaxel at the dose of 100 mg/m 2 has been the topic of three studies [72] [73] [74] . The overall reported response rate in 120 patients was 30%, similar to the results with paclitaxel in this disease.
In a phase HI study the Gynecology Oncology Group (GOG) [71] has compared the combination of paclitaxel 135 mg/m 2 and cisplatin 75 mg/m 2 (CT) every 3 weeks for 6 cycles with the combination of cyclophosphamide 750 mg/m 2 and cisplatin 75 mg/m 2 (CP) in 388 eligible previously untreated patients with stage HI-TV debulked ovarian cancer with residual disease of >1 cm. The response rate was significantly (p < 0.01) better for CT (79%) than for CP (63%), as was survival (17.9 months and 13.8 months respectively), but neutropenia was also significantly more pronounced with CT and cardiotoxicity was seen only with this regimen. Nevertheless, these data are important and if they are confirmed in similar studies and if survival differences persist with longer follow-up they sug- (Table 5) Both taxanes have been extensively studied in metastatic breast cancer although phase HI studies have not yet been reported. The first reported phase II study on paclitaxel [75] indicated an overall 56% response rate in 25 evaluable patients, 14 of whom received only prior adjuvant chemotherapy while 11 had previously been treated with chemotherapy for metastatic disease. For interpretation purposes, in the following we will take into account only prior chemotherapy for metastatic disease; thus, first-line treatment in metastatic disease combines the data obtained in patients with or without prior adjuvant chemotherapy. In most studies the percentage of patients previously treated with adjuvant chemotherapy ranges between 25% and 40%. Using a dose of 250 mg/m 2 as a 24-hour infusion the investigators observed 3 complete and 11 partial responses, with a median response duration of 5 + months [75] . A confirmatory study using the same dose with the addition of G-CSF resulted in an overall response rate of 62% in 26 patients receiving the drug as firstline chemotherapy [76] . Both studies were performed as single-institution studies. In a large multicenter multinational European study including 471 patients, lower doses of paclitaxel were administered and compared (135 and 175 mg/m 2 , respectively) using a Table 5 . Phase II studies in breast cancer. 3-hour infusion. Response rates have sometimes been reported without giving patient numbers [77] , but they seem to indicate some dose-response relationship (Table 5) . Second-line chemotherapy with paclitaxel results in lower but still very interesting response rates, varying from 16% to 44%, depending on dose (Table  5) , and even 3rd-and 4th-line paclitaxel induces responses, which is uncommon with other cytotoxic drugs in this disease.
Breast cancer
Docetaxel is at least similarly active. In three independent studies in first-line chemotherapy, response rates varied from 70% to 75% [81] [82] [83] , which is even more interesting, considering the total numbers of patients and the fact that two of the studies were multicenter studies which usually have lower response rates than do single-center studies. Amazingly, the response rate in second-line chemotherapy (62%) [84, 85] is only slightly lower than in first-line chemotherapy, which again is an uncommon observation.
Docetaxel also frequently induces responses in liver metastases -another unusual observation [81] . Thus, although randomized studies have not yet been performed, which precludes a definitive comparison, the data seem to suggest a higher activity for docetaxel in metastatic breast cancer.
Since multi-drug resistance has been suggested as one of the mechanisms of resistance related to taxanes and anthracyclines, taxane treatment has also been studied in known anthracycline-resistant disease, yielding response rates of 6%-53% for paclitaxel and of 60% for doxetaxel (Table 6) , which indicates a lack of full cross-resistance. However, these data are still immature because of the low number of patients included in presently available reports. (Table 7) Both taxanes yielded activity in phase II studies in nonsmall cell lung cancer. For paclitaxel the response rate was 22% in non-pretreated patients, while for docetaxel it was 28% in a similar population [88] [89] [90] [91] [92] . Interestingly, docetaxel retains its activity in 2nd-line chemotherapy in this disease, which is seldom studied because of the extremely poor prognosis of these pa- Table 6 . Taxanes in doxombicin-resistant breast cancer. tients [91] , further underscoring the importance of the latter observation. Although the median duration of response was relatively short, the lack of active drugs in the treatment of this disease suggests that studies combining taxanes with drugs such as cisplatin should be assigned priority. Data on the activity of taxanes in small-cell lung cancer are rather limited. Paclitaxel was tested as first-line chemotherapy in 32 patients, yielding a response rate of 34% [93] , while docetaxel was tested in second-line chemotherapy in 18 patients, resulting in a response rate of 28% [94] .
Other tumors
In head and neck cancer both paclitaxel and docetaxel are very active, yielding response rates of 43% and 44%, respectively [95, 96] , in a disease stage that usually responds poorly to chemotherapy and where methotrexate is still considered the standard drug. Recent studies with the latter drug indicated a response rate of only 15% in a similar patient population.
In 2 malignant melanoma studies including a total of 87 patients, paclitaxel yielded a response rate of 14% [97, 98] , while docetaxel, in a not yet confirmed study, appears to be slightly more active, with a response rate of 25% [99] . Again, it should be noted that there are no randomized comparisons.
There also appears to be a suggestion that docetaxel has higher potency in gastric cancer while paclitaxel at a dose of 250 mg/m 2 yielded a disappointing response rate of 5% in non-pretreated patients [100] , docetaxel resulted in 26% responses in this patient population [101] .
In pancreatic cancer the respective response rates of paclitaxel and docetaxel were 13% and 21% [102, 103] . In colorectal, renal and prostatic cancer no activity of any importance was observed [104] [105] [106] [107] [108] .
Finally, docetaxel was identified as one of the few active drugs in soft tissue sarcomas [109] . (Table 8) Many hundreds of patients with different types of tumors have now been treated with different doses of paclitaxel and the docetaxel regimen outlined above. In general, along with similarities, Table 8 suggests different toxicity profiles for the two drugs.
Toxic effects in phase II studies
The most frequently occurring side effects reported in published studies are listed in Table 8 . For both drugs alopecia is common and usually universal. It occurs 2-4 weeks after the start of treatment and is fully reversible after treatment discontinuation.
Both drugs also frequently induce short-lasting neutropenia. The incidence of grade 4 leuko-/granulocytopenia approximates 50%-55%. The onset is quite rapid, with the nadir occurring on days 5-8 followed by a very rapid recovery. Dose delays for persisting myelosuppression are very rare. The short duration of leuko-/ granulocytopenia is also reflected in the number of concomitant infections, which is low in relation to the severity of leuko-/granulocytopenia, although they appear to be more numerous with the higher doses of paclitaxel given by 24-hour infusion. Thrombocytopenia is infrequent and rarely severe.
Nausea and/or vomiting, still the most distressing side effects of chemotherapy, are hardly a problem with taxanes; They occur relatively infrequently and are easily counteracted by the prophylactic use of conventional anti-emetics during subsequent courses. The routine use of 5HT 3 antagonists is not necessary.
Diarrhea and mucositis are usually mild, the latter occurring slightly more frequently with docetaxel, while mild arthralgia/myalgias appear to be more common with paclitaxel. In most instances, the arthralgia/myalgia occurs after a few days, is generally mild, responds to simple analgetics, and disappears rapidly; it is, however, occasionally bothersome to the patient. Without premedication, hypersensitivity reactions are far more frequently reported and appear to be more severe for paclitaxel than for docetaxel. However, all phase II studies with paclitaxel included the standard use of premedication which largely reduced the incidence and severity of the hypersensitivity reactions (Table 8) , while the number of hypersensitivity reactions to docetaxel given in the table relates to treatments without premedication. Most of the hypersensitivity reactions to docetaxel occur during the first 2 cycles [110] and always within minutes after the start of the infusion. The overall incidence is approximately 25% [110] [111] [112] . In patients receiving subsequent cycles without prophylactic measures there is an approximately 30% incidence of subsequent hypersensitivity reactions [110] , which suggests a spontaneous diminishment of this side effect. Thus, the dramatic decrease in the incidence after the second cycle cannot be explained solely by the addition of premedication. The application of premedication, including corticosteroids, has markedly reduced the incidence of hypersensitivity reactions [112] , which are no longer considered a major clinical problem.
Skin toxicity consisting of erythema, desquamation and infrequent exfoliation on the one hand, and/or nail toxicity consisting of calcification and sometimes painful and incapacitating onycholysis on the other, are mainly seen with docetaxel, while with paclitaxel rashes are sometimes seen. The use of corticosteroid regimens in the prophylaxis of hypersensitivity reaction has not reduced the incidence of docetaxel-related skin toxicities [111] but it must be borne in mind that none of the patients received premedication starting with course 1. Studies addressing this topic are presently ongoing.
The other unusual and uncomfortable side effect of taxanes is fluid retention, which seems to be more pronounced with docetaxel. Any type of fluid retention may occur. Most frequently it consists of peripheral edema, but pleural effusions and ascites have also been reported. For docetaxel the fluid retention appears to be related to the cumulative dose. At cumulative doses of <400 mg/m 2 it is infrequent, but at a dose of > 400 mg/m 2 its incidence rapidly increases [111] . There are data which suggest that corticosteroid premedication may also reduce the incidence of this side effect [111, 112] , but confirmative prospective studies are needed before definitive conclusions can be drawn.
Mild peripheral neuropathy has frequently been reported with paclitaxel. It is dose-related and reversible [113] and can become dose-limiting at higher doses and in combination with other neurotoxic drugs such as cisplatin. Neurotoxicity appears only rarely with docetaxel. Cardiotoxicity, either supraventricular rhythm disturbances [114] or cardiac function abnormalities, have been reported only as a relatively infrequent side effect of paclitaxel, but routine cardiac monitoring is not mandatory [115] .
N.S. -not stated.
Future perspective
It is clear that the taxane drugs will be a major addition to the presently available classes of drugs. Nevertheless, several questions concerning the two presently clinically available representatives need to be answered. For paclitaxel the optimal dose and infusion schedule should be identified, also taking into account patient convenience.
Its combination with other drugs also needs to be investigated in detail, partly in view of preliminary data showing important sequence-dependence in vitro as well as in clinical studies. For docetaxel, measures to prevent nail toxicity and fluid retention will be essential, and it may be important as well to try to further reduce paclitaxel-related neuro-and cardiac toxic effects. Studies on combinations of docetaxel with other cytotoxic drugs will also be performed in the next few years. Preclinical data on sequence dependence such as those now available for paclitaxel have not yet been reported for docetaxel.
Obviously, ways to enable environment-friendly bulk production of paclitaxel by semisynthesis are being explored and the early reports suggest positive results from these efforts. As the mechanism of action of these drugs is new, analogue development will undoubtedly be one of the main topics in the next few years.
